ALIM vs. HROW, DNTH, ABUS, MLYS, SLN, PHAR, ORIC, ZYME, SVRA, and TVTX
Should you be buying Alimera Sciences stock or one of its competitors? The main competitors of Alimera Sciences include Harrow (HROW), Dianthus Therapeutics (DNTH), Arbutus Biopharma (ABUS), Mineralys Therapeutics (MLYS), Silence Therapeutics (SLN), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), Zymeworks (ZYME), Savara (SVRA), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical preparations" industry.
Harrow (NASDAQ:HROW) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.
In the previous week, Harrow had 2 more articles in the media than Alimera Sciences. MarketBeat recorded 5 mentions for Harrow and 3 mentions for Alimera Sciences. Harrow's average media sentiment score of 1.58 beat Alimera Sciences' score of 1.31 indicating that Alimera Sciences is being referred to more favorably in the news media.
Harrow has a net margin of -22.59% compared to Harrow's net margin of -23.74%. Alimera Sciences' return on equity of -39.82% beat Harrow's return on equity.
Alimera Sciences received 275 more outperform votes than Harrow when rated by MarketBeat users. Likewise, 57.70% of users gave Alimera Sciences an outperform vote while only 56.25% of users gave Harrow an outperform vote.
Alimera Sciences has lower revenue, but higher earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.
Harrow currently has a consensus price target of $29.80, suggesting a potential upside of 66.02%. Alimera Sciences has a consensus price target of $8.00, suggesting a potential upside of 162.30%. Given Harrow's higher possible upside, analysts clearly believe Alimera Sciences is more favorable than Harrow.
72.8% of Harrow shares are held by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are held by institutional investors. 13.7% of Harrow shares are held by company insiders. Comparatively, 31.4% of Alimera Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Harrow has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
Summary
Alimera Sciences beats Harrow on 10 of the 17 factors compared between the two stocks.
Get Alimera Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alimera Sciences Competitors List
Related Companies and Tools
